SAGE-547 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Super-Refractory Status Epilepticus
Conditions
Super-Refractory Status Epilepticus
Trial Timeline
Jun 1, 2015 → Aug 11, 2017
NCT ID
NCT02477618About SAGE-547 + Placebo
SAGE-547 + Placebo is a phase 3 stage product being developed by Supernus Pharmaceuticals for Super-Refractory Status Epilepticus. The current trial status is completed. This product is registered under clinical trial identifier NCT02477618. Target conditions include Super-Refractory Status Epilepticus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02614547 | Phase 2 | Completed |
| NCT02477618 | Phase 3 | Completed |
Competing Products
2 competing products in Super-Refractory Status Epilepticus